Binetrakin

Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.1% of U.S. adults, impairing quality of life. FDA-approved biologics (dupilumab, mepolizumab, omalizumab) target type 2 inflammation, showing efficacy in reducing polyp size and improving symptoms. Optimal use, treatment duration, and patient selection for biologics remain unclear, necessitating further research and shared decision-making.

EMA approves Sanofi/Regeneron’s Dupixent for EoE in children aged 1-11, weighing at least 15kg, based on EoE KIDS trial results. Dupixent is the first approved treatment for these young patients, with efficacy and safety consistent with its profile in adolescents and adults.

Sanofi and Regeneron's Dupixent approved by EC for EoE in children aged 1-11 years, weighing at least 15kg, not controlled by conventional therapy. Dupixent showed 68% histological remission vs 3% placebo in phase 3 EoE KIDS trial, with sustained results up to one year.

EMA approves Sanofi and Regeneron's Dupixent for treating eosinophilic esophagitis in children aged 1-11 years, marking the first EU approval for this age group. Dupixent, a monoclonal antibody targeting IL4 and IL13 pathways, showed efficacy in a phase 3 trial, with 68% of children achieving histological disease remission.

EMA approved Sanofi/Regeneron’s Dupixent for EoE in children aged 1-11, based on EoE KIDS trial results. Dupixent is the first approved treatment for young EoE patients in EU, Canada, and US.

The European Medicines Agency approved Dupixent for treating eosinophilic esophagitis in children aged one to 11 years, based on phase 3 data showing significant histological disease remission at 16 weeks, sustained up to one year. Dupixent is the first medicine in the EU indicated for these young patients, addressing a critical need where growth is crucial.

European Commission approves Dupixent for treating eosinophilic esophagitis in children aged 1 to 11, based on Phase 3 data showing significant histological disease remission at 16 weeks, sustained up to one year. Dupixent is the first medicine in the EU for this age group, addressing a critical need for young patients struggling with eating and growth.

Scientists at Icahn School of Medicine discovered ovarian cancer tumors produce interleukin-4 (IL-4) to resist immunotherapy, suggesting IL-4 blocking drugs could enhance immunotherapy for ovarian cancer.

Christopher Bunick, MD, PhD, discusses new standards in atopic dermatitis care, emphasizing EASI 90 and itch reduction. He presents on systemic therapies, JAK inhibitor safety, and biologics' differences, advocating for better long-term safety and efficacy over corticosteroids. Bunick also highlights the importance of achieving both skin clearance and itch control for improved patient quality of life.